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Abstract	  26	  
Background:	  27	  
Antibiotic prophylaxis (AP) administered prior to invasive procedures in patients at 28	  
risk of developing infective endocarditis (IE) has historically been the focus of IE 29	  
prevention. Recent changes in AP guidelines in the US and Europe have substantially 30	  
reduced the numbers for whom AP is recommended. In the UK, the National Institute 31	  
for Health and Care Excellence (NICE) guidelines recommended complete cessation 32	  
of AP in March 2008. We report the impact of these guidelines on AP prescribing; in 33	  
addition, IE incidence was examined following the introduction of the guidelines.	   34	  
Methods:	  	  35	  
We analyzed English AP prescribing data from January 2004 to March 2013 and 36	  
hospital discharge episode statistics for patients with a primary diagnosis of IE from 37	  
January 2000 to March 2013. 38	  
Findings:	  	  39	  
AP prescribing rates fell dramatically after introduction of the NICE guidance (10,935 40	  
prescriptions/month vs. 2,236 prescriptions/month, p<0·0001). Commencing in 41	  
March 2008, there was also a significant increase in the number of IE cases/month 42	  
(0·11 cases/10million/month, CI 0·05-0·16, p<0·0001) above the projected historical 43	  
trend. By March 2013, there were an additional 35 cases/month than would have been 44	  
expected if the previous trend had continued. This increase in IE incidence was 45	  
significant for both ‘high-risk’ and ‘lower-risk’ individuals. 46	  
Interpretation:	  	  47	  
Although our data do not establish a causal relationship, there has been a substantial 48	  
reduction in AP prescribing and a significant increase in IE incidence in England 49	  
since introduction of the NICE guidelines in 2008. 50	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55	  
Introduction	  56	  
Infective endocarditis (IE) is uncommon, but has high morbidity and mortality.1 Oral 57	  
viridans group streptococci (VGS) are implicated as causal organisms in 35-45% of 58	  
cases.2-5 Antibiotic prophylaxis (AP) prior to invasive dental procedures has been the 59	  
focus for preventing IE for over 50 years and remains the standard of care for ‘high-60	  
risk’ patients in most parts of the world.6,7 The aim of AP is to reduce or eliminate 61	  
bacteremia8-11 that can cause IE in susceptible individuals. There has never been a 62	  
randomized clinical trial of AP12 and there is little evidence to support its 63	  
effectiveness.2,4,9   64	  
Until recently, it was the standard of care in most parts of the world to provide AP to 65	  
patients at ‘high-risk’ (previous IE, prosthetic heart valves or valves repaired with 66	  
prosthetic material, unrepaired cyanotic congenital heart disease, or certain repaired 67	  
congenital heart defects) and ‘moderate-risk’ (previous rheumatic fever, heart 68	  
murmur, or evidence of native valve disease) of IE. In March 2008, the UK National 69	  
Institute for Health and Care Excellence (NICE) produced new guidance 70	  
recommending complete cessation of AP.13-15 In contrast, the American Heart 71	  
Association (AHA)7 and European Society of Cardiology (ESC)6 produced new 72	  
guidelines in 2007 and 2009, respectively, recommending cessation of AP for 73	  
‘moderate-risk’ patients only. 74	  
The NICE guidance provided an opportunity for a retrospective secular trend study, 75	  
analyzed as an interrupted time series, of the effect of AP versus no prophylaxis on 76	  
the incidence of IE in the entire population of England (population 53·7 million). In a 77	  
preliminary study, just two years after the introduction of the NICE guidelines, no 78	  
significant increase in IE incidence was seen despite a 78% reduction in AP 79	  
prescribing.16 However, concerns were expressed that two years was too soon to 80	  
detect a clinically significant change.17 Moreover, 2,500 AP prescriptions/month were 81	  
still being issued at this point, with evidence of targeting of ‘high-risk’ individuals.18 82	  
Therefore, the aim of the present study was to examine the effect of the NICE 83	  
guidelines on AP prescribing and IE incidence over a longer time frame. 84	  
 85	  
  86	  
Methods	  	  87	  
Prior to introduction of the NICE guidelines, a single 3g dose of oral amoxicillin (or a 88	  
600mg dose of oral clindamycin in penicillin allergic individuals) was prescribed 89	  
before invasive dental procedures as AP to those at ‘moderate-risk’ or ‘high-risk’ of 90	  
developing IE. This dose, timing and mode of administration of amoxicillin and 91	  
clindamycin are almost uniquely associated with AP prescribing to cover invasive 92	  
dental procedures in the UK.16 Data on AP prescribing from January 2004 to March 93	  
2013 were obtained from the National Health Service Business Services Authority 94	  
(www.ppa.org.uk/ppa/ppa_main.htm). 95	  
IE incidence data and associated in-hospital mortality from January 2000 until March 96	  
2013 were obtained using national hospital episode statistics (HES) of inpatient 97	  
hospital activity, as previously described.16 All patients admitted to United Kingdom 98	  
hospitals have standard data recorded, including their primary discharge diagnosis 99	  
(and up to 12 secondary diagnoses) using the ICD-10 coding system 100	  
(http://apps.who.int/classifications/apps/icd/icd10online). These anonymized data are 101	  
reported to the warehouse of the Secondary Uses Service 102	  
(www.connectingforhealth.nhs.uk/systemsandservices/sus). 103	  
All patients (including those who died in hospital) with a primary diagnosis of “acute 104	  
or subacute infectious endocarditis” in any episode (ICD-10 code I33.0) were 105	  
identified. Patients admitted to one hospital and transferred to another as part of their 106	  
management (so called “superspells”) were identified using standardized 107	  
methodology19 and counted only once. Hospital admissions are recorded as 108	  
emergency or elective. Elective admissions are subdivided into booked (patient 109	  
admitted having been given a date at the time the decision to admit was made, 110	  
determined mainly on the grounds of resource availability), waiting list (patient 111	  
admitted electively from a waiting list having been given no date of admission at a 112	  
time a decision was made to admit) and planned (patient admitted, having been given 113	  
a date or approximate date at the time that the decision to admit was made). We 114	  
included only emergency, booked and planned admissions. 115	  
Incidence of IE was corrected for changes in the size of the English population and 116	  
compared before and after introduction of the NICE guideline using segmented 117	  
regression analysis of the interrupted time series20 using R.21 Examining the partial 118	  
autocorrelation function for the dataset confirmed that no adjustment for seasonality 119	  
was required. To allow for autocorrelation in the data, the segmented regression 120	  
described20 was fitted using R's gls function from the nlme package.22 This package 121	  
allows for the regression model to be estimated under the condition of autocorrelation. 122	  
The order of autocorrelation was obtained by examining both the autocorrelation and 123	  
partial autocorrelation functions. To confirm robustness of the segmented regression, 124	  
change-point-analysis was used to calculate the optimal positioning and number of 125	  
data change-points using the R change-point package that implements the Hinkley 126	  
algorithm.23 127	  
Analysis of secondary codes and correlation with preceding hospital admissions at the 128	  
individual patient level were used to identify cases that had been at ‘high-risk’ of 129	  
developing IE, as defined by AHA7 and ESC6 guidelines. All other patients were 130	  
regarded as having been at ‘lower-risk’ (i.e. ‘moderate’ or ‘low-risk’). Additional 131	  
details are provided in the Appendix. Secondary and supplemental codes were also 132	  
used to try and identify the causal organisms for each case of IE (see Appendix for 133	  
methodology) 134	  
HES data were used to identify and quantify other variables that might influence the 135	  
incidence of IE over time.  Thus, annual data were collected regarding (i) the number 136	  
of individuals undergoing valve replacement, valve repair, or percutaneous valve 137	  
implantation, (ii) new in-patient diagnoses of cyanotic congenital heart disease, (iii) 138	  
surgical or percutaneous procedures in congenital heart disease patients, and (iv) the 139	  
number of cardiovascular implantable electronic devices (CIEDs).24 Finally, data were 140	  
obtained from the NHS Business Authority to demonstrate the number of individuals 141	  
accessing primary care dental services between March 2006 and December 2013 142	  
(expressed as a percentage of the adult and child [under 18] population of England). 143	  
Role	  of	  the	  funding	  source	  144	  
The funders of the study had no role in the study design, data collection, data analysis, 145	  
data interpretation or writing of the report. MT and MD had access to the prescribing 146	  
data and SJ and MD had access to the hospital episode statistics data. All the authors 147	  
had final responsibility for the decision to submit for publication.  148	  
 149	  
150	  
Results 151	  
Change	  in	  antibiotic	  prophylaxis	  prescribing	  	  152	  
Before 2008, the rate of AP prescribing had remained relatively constant for many 153	  
years.  However, following the introduction of NICE guidelines concerning cessation 154	  
of AP, there was a highly significant reduction in the mean number of AP 155	  
prescriptions/month (pre-NICE: 10,900, post-NICE: 2,236; p<0·0001). In the last six 156	  
months studied, this fell further to an average of 1,307 prescriptions/month (Figure 1). 157	  
The vast majority of prescriptions were for amoxicillin (Figure 1a) with 158	  
approximately 90% issued by dentists (Figure 1b). 159	  
Change	  in	  the	  incidence	  of	  infective	  endocarditis	  	  160	  
19,804 patients with a primary diagnosis of IE were identified between January 2000 161	  
and March 2013. 17,031 (86%) were emergency admission and 2,773 (14%) were 162	  
booked or planned admissions (usually because of lack of beds, because the patient 163	  
needed to make arrangements before admission or because the general practitioner 164	  
had discussed the patient directly with a hospital specialist and the patient had been 165	  
booked for admission without the patient passing through the emergency department). 166	  
Before March 2008, there was a consistent upward trend in the population-corrected 167	  
IE incidence in England (Figure 2). However, soon after implementation of the NICE 168	  
guidelines there was a significant increase in the slope of this trend line (0·11 169	  
cases/10million/month, CI 0·05-0·16, p<0·0001) that was also seen in the uncorrected 170	  
incidence data (Appendix Figure S1). By March 2013, we estimate that there were 171	  
34.9 (95% CI, 7·9 – 61·9) more IE cases/month than would have been expected if the 172	  
previous trend had continued. Because AP prescribing had fallen from a pre-NICE 173	  
mean of 10,900 to 1,235 by March 2008, a fall of 9,665 (89%), we can approximate  174	  
that 276.8 (95% CI, 156·1 – 1217·3)  AP prescriptions would be required to prevent 175	  
one case of IE. Even with the March 2012 outlier value removed, the upward change 176	  
in the trend line slope remained significant for the population-corrected (Figure 2) and 177	  
uncorrected data (Appendix Figure S1). Both ‘high-risk’ and ‘lower-risk’ individuals 178	  
were affected by this increase (Figure 3) with a statistically significant increase in 179	  
both trend lines (p=0·025, p=0·0002, respectively). A significant change was also 180	  
seen in the uncorrected ‘high-risk’ and ‘lower-risk’ data (Appendix Figure S3). A 181	  
break down of IE incidence in different ‘high-risk’ categories is provided in Figure 4 182	  
(and Appendix Table S2). 183	  
At the same time, there was a non-significant increase in the slope of population-184	  
corrected IE-associated mortality (0·01 cases/10 million/month, CI -0·01-0·02, 185	  
p=0·394; Figure 2) that was replicated in the uncorrected data (Appendix Figure S1). 186	  
‘Change point analysis’ of the population-corrected (Figure 5) and uncorrected 187	  
(Appendix Figure S2) IE incidence data shows that the change in IE incidence 188	  
occurred in June 2008, three months after the change in AP guidelines. This three 189	  
months lag is plausible since the incubation period of IE is usually less than six weeks 190	  
and HES data capture the discharge diagnosis – in 2008 the median duration of 191	  
hospital stay for patients in this study was 25 days. 192	  
Comparing patients diagnosed with IE before and after March 2008 however, there 193	  
was no significant change in the sex distribution (before - male 10,606 (69%), female 194	  
4,823 (31%); after - male 2963 (68%), female 1411 (32%), (p=0·394)), age 195	  
(mean±SD, 59·0 years ±20·3 before; 59·3 years ±20·8 after (p=0·139)) or median 196	  
length of stay in hospital (24 days before; 25 days after (p=0·224)). 197	  
Pathogen-specific secondary or supplementary causal organism coding of IE cases 198	  
was unevenly distributed and increased from 30% to 49% over the study period. The 199	  
rate of increase was also uneven and diminished over the last 3 years of the study. 200	  
Furthermore, there were no specific codes that could be used to identify oral viridans 201	  
group streptococci (OVGS). As a consequence it was impossible to draw any 202	  
meaningful information from this data with regard to the effect of the change in AP 203	  
prescribing on the nature of the organisms responsible for cases of IE.  204	  
Other	  factors	  that	  could	  have	  influenced	  the	  incidence	  of	  infective	  endocarditis	  205	  
HES data were used to quantify several other variables that might influence the 206	  
incidence of IE over time (further details provided in the Appendix), including; (i) the 207	  
number of individuals undergoing valve replacement, valve repair, or percutaneous 208	  
valve implantation (Appendix Figure S4a), (ii) new in-patient diagnoses of cyanotic 209	  
congenital heart disease (Appendix Figure S4b), (iii) surgical or percutaneous 210	  
procedures in congenital heart disease patients (Appendix Figure S4b), (iv) the 211	  
number of cardiovascular implantable electronic devices (CIEDs) (Appendix Figure 212	  
S4c) and (v) the number of individuals accessing primary care dental services 213	  
(Appendix Figure S4d).	  214	  
 215	  
Discussion	  216	  
Summary	  of	  the	  findings	  217	  
Since introduction of the NICE guidelines in March 2008, which recommended 218	  
cessation of AP to prevent IE, there has been both a highly significant fall in AP 219	  
prescribing and a significant increase in the incidence of IE in England. This rise has 220	  
affected both ‘high-risk’ and ‘lower-risk’ individuals. Although there was an increase 221	  
in IE-associated in-hospital mortality, this did not reach statistical significance, 222	  
possibly because of the lower mortality associated with IE due to oral streptococci, 223	  
the general fall in IE mortality and the lack of statistical power resulting from the 224	  
smaller number of mortalities. 225	  
Possible	  implications	  226	  
Of paramount importance is whether the fall in AP prescribing was responsible for the 227	  
increase in IE incidence. Although there was a temporal association, we were not able 228	  
to prove a causal relationship.  229	  
We previously analyzed these data two years after the introduction of the NICE 230	  
guidelines. At that time, a significant increase in IE incidence was not demonstrable 231	  
despite a highly significant 78.6% reduction (p<0·0001) in AP prescribing.16 232	  
The impact of the 2007 AHA guidelines was examined in four investigations and no 233	  
increase in IE incidence was observed following their implementation.25-28 However, 234	  
all of these US studies involved either a smaller population size and/or a shorter 235	  
period of follow up than the present assessment. One study was performed only nine 236	  
months after the change in guidelines and included only 396 cases.27 Another, 237	  
performed three years after the introduction of the guidelines, was restricted to 238	  
children and included 1157 cases of IE.26 The third used Medicare records to identify 239	  
the incidence of IE in approximately 75% of older adult Medicare beneficiaries for 240	  
around 2·5 years after introduction of the AHA guidelines.28 The fourth25 contained 241	  
two different cohorts. First, an in depth study on the incidence of IE in Olmsted 242	  
County (adult population <150,000) over three years following introduction of the 243	  
guidelines. Second, a much larger study using ICD-9 coding data from the 244	  
Nationwide Inpatient Sample (NIS) database, that contains a ~20% stratified sample 245	  
of US community hospitals.25 This study more closely matched our own, but only 246	  
examined IE incidence for two years following the AHA guidelines update. Although 247	  
our initial assessment, two years after the introduction of the NICE guidelines, 248	  
demonstrated no change in IE incidence,16 the present more sophisticated re-analysis 249	  
after five years has detected a significant change. 250	  
Similarly, Duval et al reported a follow up study in three French regions (population 251	  
~11 million adults)29 where a guideline change in 2002 restricted AP to patients at 252	  
‘high-risk’ (approximately 10% of the total). They found no significant increase in the 253	  
incidence of oral streptococcal IE in 2008 compared with their findings in 1991 and 254	  
1999. Although these data were collected six years after the guideline change, the 255	  
methodology was different and the population size studied smaller than the current 256	  
study.  Moreover, AP remained the standard of care for ‘high-risk’ patients in both the 257	  
US and French studies. 258	  
Our estimate of the number of AP prescription needed to prevent one case of IE is 259	  
considerably lower than other estimates.30,31 Our data is based on prescribing data and 260	  
IE incidence data obtained from a large population. Nonetheless, it is associated with 261	  
large CI and assumes a link between the prescribing and incidence data that may not 262	  
be true. Other estimates also make assumptions and are generally derived from 263	  
complex calculations using estimated figures derived from relatively small sample 264	  
size populations. Such calculations based on multiple estimates tend to multiply the 265	  
uncertainty but are nonetheless valid. 266	  
On the positive side, dental management of patients at risk of IE has been simplified 267	  
by the NICE guidelines and the fall in AP prescribing will have reduced AP 268	  
prescribing costs and the number of AP related adverse drug reactions. 269	  
Limitations	  270	  
There are several limitations to this study. The data rely on UK hospital coding and 271	  
may not be generalizable to other populations. In the UK, data are collected on every 272	  
patient admitted to hospital by trained and accredited coders. Although these data are 273	  
subject to error, they have been shown, for example, to provide more reliable and 274	  
complete data capture for vascular surgery than a UK national research database 275	  
specifically designed for that purpose.32 Furthermore, as the coding was undertaken 276	  
independently of our study, it was not subject to bias or influenced in any other way 277	  
by introduction of the NICE guidelines. Moreover, the size and scale of the data set 278	  
and consistency of the underlying coding process are likely to negate the impact of 279	  
any systematic error. Although IE may present to different hospital specialties and 280	  
cause difficulties in initial diagnosis, HES data record the final diagnosis for each 281	  
episode, and should reflect as accurately as possible the number of IE cases treated. 282	  
Nonetheless, the diagnosis of IE is sometimes uncertain and will not always have 283	  
been based on the Duke criteria.33 Furthermore, because of the high mortality and 284	  
morbidity associated with IE, clinicians may treat some cases as IE even when the 285	  
diagnosis is uncertain. Undoubtedly, therefore, some cases will have been miscoded. 286	  
ICD-10 and OPCS-4 codes were used to identify episodes of IE occurring in 287	  
individuals at ‘high-risk’ of IE. This required us to look backwards in time from the 288	  
index case of IE to identify previous episodes of IE, pre-existent cyanotic congenital 289	  
heart disease and previous operative procedures (such as valve surgery) that would 290	  
have defined the individual as ‘high-risk’. However, since some of these searches 291	  
were limited and reliant on accurate recording of risk factors, it is likely we 292	  
underestimated the number of ‘high-risk’ individuals. We also assumed that IE cases 293	  
that did not arise in a ‘high-risk’ individual must have occurred in individuals who 294	  
were at ‘moderate-risk’ or ‘low-risk’. Since we could not distinguish these groups 295	  
using HES data, we clustered them together as ‘lower-risk’ cases. It is possible that a 296	  
small number of ‘high-risk’ individuals were erroneously included resulting in 297	  
overestimation of the size of the lower-risk group. 298	  
The pathogen-specific causal organism data had major limitations: (i) 299	  
secondary/supplementary coding was unreliable, (ii) relevant codes were recorded in 300	  
only 30-49% of cases and we cannot be certain that these represented a random subset 301	  
of the entire IE population, (iii) the rate of improvement in secondary/supplementary 302	  
coding was uneven (iv) there are no pathogen-specific ICD-10 codes that identify 303	  
OVGS, (v) we could not be certain that the organism coded was the pathogen 304	  
responsible for IE and not some other intercurrent infection, (vi) because of the small 305	  
amount of data for each type of organism it was underpowered to detect a significant 306	  
change. 307	  
Given these limitations, it was impossible to draw any conclusions from the 308	  
organism-specific data with regard to the change in AP prescribing. 309	  
Although we have demonstrated a rise in the number of cases of IE, there are many 310	  
factors other than the change in the AP guidelines in March 2008 that could be 311	  
responsible. For example, there may have been a sudden large increase in the number 312	  
of individuals at risk of IE. However, for many of those factors that put an individual 313	  
at ‘high-risk’ from IE we have demonstrated that this is unlikely to be the case (see 314	  
Appendix for details). Using HES data, an overall annual increase in the number of 315	  
prosthetic heart valve and valve repair procedures was demonstrated over the study 316	  
period, but no sudden change in procedural volume that could account for the increase 317	  
in IE incidence. Similarly, the number of surgical procedures for congenital heart 318	  
disease was almost constant over the period, and while there was a dramatic increase 319	  
in the number of percutaneous procedures performed for congenital heart disease in 320	  
2005-6, this fell subsequently from 2009/2010 onwards. There was no sudden change 321	  
in the annual rates of pacemaker or cardioverter-defibrillator insertion. However, we 322	  
were unable to obtain data for other groups of individuals potentially at risk of 323	  
developing IE such as diabetics, the elderly or those living in residential care. 324	  
Nonetheless, publically-available data on the prevalence of diabetes in England shows 325	  
a steady rise in the number of individuals with diabetes from 2,088,335 in 2007/8 to 326	  
2,455,937 in 2010/11 and this appears to be part of a long term trend.34 Similarly, the 327	  
number of individuals age 65 or over living in residential care in England has 328	  
remained static between 2001 (290,000) and 2011 (291,000) but fallen as a proportion 329	  
of the total population over 65 from 3·5% in 2001 to 3·2% in 2011.35 330	  
Alternatively, IE incidence could have increased due to susceptible individuals being 331	  
exposed to more risk prone procedures and bacteremias. Although we identified no 332	  
significant change in the proportion of the English population receiving dental 333	  
treatment, we were unable to study more subtle changes in the pattern of dental care, 334	  
standards of oral hygiene, or patterns of oral disease that might influence the size and 335	  
frequency of VGS related bacteremia. Nonetheless, dental statistics for England show 336	  
dental extractions, at ~2·2 million per year, have remained fairly constant for many 337	  
years while there has been a slow increase in the 12-12·8 million scale and polish 338	  
courses of treatment per year.36 We cannot, however, know if this pattern of care is as 339	  
applicable to those at risk of IE as it is to the general population. We also don’t know 340	  
if the interest caused by the NICE guidelines, or growing knowledge about bacteremia 341	  
resulting from daily habits such as tooth brushing, will have changed the behavior of 342	  
patients at risk of IE in favor of seeking/avoiding dental care or improving/neglecting 343	  
oral hygiene. A change in the frequency of other potentially risk prone procedures 344	  
such as colonoscopy, renal dialysis, intravenous drug therapy and wound 345	  
management, could also have affected IE incidence. Data is not available on all of 346	  
these but HES data for England37 show no sudden increase in colonoscopies and data 347	  
from the UK Renal Registry show only a gradual increase in hemodyalisis between 348	  
2007-2009 and then a fall. This data also shows a fall in MRSA bacteremia rates for 349	  
all dialysis patients from 2007-2012.38 Nonetheless, we cannot exclude the possibility 350	  
that a combination of factors affecting risk prone individuals and the number of 351	  
episodes of bacteremia to which they are exposed could have caused the increase the 352	  
IE incidence had they occurred at the right time. 353	  
Although we have corrected for changes in the size of the English population, changes 354	  
in the age and sex distribution and more subtle population changes e.g. immigration 355	  
from parts of the world with high rates of rheumatic heart disease or poor oral 356	  
hygiene, might explain the change in incidence of IE if large in size and coincident 357	  
with the change in AP guidelines. Furthermore, other changes in health policy could 358	  
be possible confounders e.g. new or amended policies that altered the rate of transient 359	  
bacteremia resulting from procedures such as colonoscopy, intravenous line 360	  
placement or others, could have brought about a systematic change in IE incidence. In 361	  
addition, use of more sophisticated diagnostic tools, improved diagnostic tool 362	  
performance or changes in diagnostic strategy could have increased the number of IE 363	  
diagnoses. If such changes occurred in the same time frame as the cessation of AP, it 364	  
would be difficult if not impossible to distinguish these effects. 365	  
Conclusions 366	  
We have demonstrated both a significant reduction in AP prescribing and a significant 367	  
rise in the rate of new IE cases in England since introduction of the NICE guidelines 368	  
recommending cessation of AP in 2008. While demonstrating a temporal relationship 369	  
between the two our data do not establish a causal link. 370	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Figure	  legends:	  518	  
Figure	  1	  519	  
The total number of prescriptions for antibiotic prophylaxis (AP) dispensed each 520	  
month: (a) Division by prescription (single 3g oral amoxicillin, BLUE; single 600mg 521	  
oral clindamycin, PURPLE) (b) Division by prescriber (dentists, MAGENTA; general 522	  
medical practitioners, BLUE; nurse practitioners, RED; hospitals, BLACK). The grey 523	  
bar indicates March 2008, the month in which cessation of AP for infective 524	  
endocarditis (IE) was recommended by NICE. 525	  
Figure	  2	  526	  
The number of infective endocarditis (IE) cases (superspells) recorded each month 527	  
(solid BLACK line) and associated in-patient mortality (solid RED line). The data are 528	  
corrected for change in the size of the English population. The vertical dashed black 529	  
line indicates March 2008, the month in which cessation of antibiotic prophylaxis 530	  
(AP) for IE was recommended by NICE. The trend lines for IE incidence (dashed 531	  
BLACK lines) and associated in-patient mortality (dashed RED lines) before and after 532	  
introduction of the NICE guidelines are also shown. NOTE: with the IE cases March 533	  
2012 outlier value removed the change in the IE incidence trend line remains 534	  
statistically significant (change in level = -0·28, CI -2·27-1·7, p=0·78; change in 535	  
slope = 0·09, CI 0·04-0·14, p<0·001) 536	  
Figure	  3	  537	  
The number of infective endocarditis (IE) cases recorded each month affecting 538	  
‘lower-risk’ (solid BLACK line) and ‘high-risk’ (solid RED line) individuals. The 539	  
data are corrected for change in the size of the total English population (not for 540	  
change in the size of population at ‘high-risk’ or ‘lower-risk’ of IE). The vertical 541	  
dashed black line indicates March 2008, the month in which cessation of antibiotic 542	  
prophylaxis (AP) for IE was recommended by NICE. The trend lines for ‘lower-risk’ 543	  
(dashed BLACK lines) and ‘high-risk’ (dashed RED lines) cases before and after 544	  
introduction of the NICE guidelines are also shown.  545	  
Figure	  4	  546	  
The number of IE cases recorded each month in individuals at ‘high-risk’ of 547	  
developing IE, according to category of ‘high-risk’ status (previous IE, previous 548	  
prosthetic replacement of heart valve, previous repair of heart valve, pre-existing 549	  
congenital heart disease repaired with prosthetic material [only within the previous 6 550	  
months], pre-existing congenital heart disease with surgical shunt or conduit, pre-551	  
existing unrepaired congenital cyanotic heart condition, pre-existing artificial heart or 552	  
ventricular assist device). The vertical dashed black line indicates March 2008, the 553	  
month in which cessation of antibiotic prophylaxis for IE was recommended by 554	  
NICE.  555	  
Figure	  5	  556	  
The number of population-corrected IE cases per 10 million population per month 557	  
(solid BLACK line). The vertical dashed black line indicates March 2008, the month 558	  
in which cessation of antibiotic prophylaxis for IE was recommended by NICE. The 559	  
red lines show the result of change-point analysis, indicating that the change occurred 560	  
in June 2008. 561	  
  562	  
Research	  in	  Context	  563	  
 564	  
Updated guidelines concerning the role of antibiotic prophylaxis to prevent infective 565	  
endocarditis vary in different nations but all share a common theme – the number of 566	  
patients in whom antibiotic prophylaxis is recommended has been markedly reduced 567	  
since there are no robust data to support its efficacy and some concerns regarding 568	  
safety. Ongoing surveillance has been recommended to ensure that reduced use of 569	  
antibiotic prophylaxis does not result in an increase in the incidence of infective 570	  
endocarditis.  Population-based surveys are required and the data outlined in the 571	  
present study represent an extremely large database upon which to base conclusions.  572	  
Although we are unable to prove a causal link between the cessation of antibiotic 573	  
prophylaxis and the increase in incidence of infective endocarditis, further 574	  
investigation is now warranted to define an explanation and determine whether other 575	  
populations demonstrate similar trends.  576	  
